Ipamorelin

To buy ipamorelin peptide South Africa-side in 2026, expect to pay roughly R400–R600 per 5 mg standalone vial, or R900 for the SA Peptides CJC-1295 5 mg / Ipamorelin 5 mg blend. Ipamorelin is a selective GHSR-1a agonist originally characterised by Raun et al. (Novo Nordisk, 1998), prized in research settings for stimulating pulsatile GH release without measurable prolactin or cortisol spill-over, the peptide's selectivity for the ghrelin receptor avoids off-target activation of corticotrophs and lactotrophs.

Key Takeaways

• Ipamorelin is a selective GHSR-1a agonist pentapeptide (711.85 g/mol) that triggers GH release without prolactin or cortisol elevation, distinguishing it from GHRP-6 and GHRP-2.
• South African research-grade ipamorelin costs R400–R600 per 5 mg vial; the CJC-1295 + ipamorelin blend costs R900 and is the most commonly stocked local format.
• Ipamorelin is not SAHPRA-registered as of 2026 and falls under unregistered-medicine provisions of Act 101 of 1965; research-use-only material sits in a separate regulatory category from human-administration products.
• The dual-axis stack (ipamorelin + CJC-1295) exploits two independent somatotroph receptors and produces synergistic GH elevation because the two intracellular cascades converge on exocytosis.
• All current research applications are pre-clinical; no Phase II or Phase III ipamorelin trial has been registered since 2023.
• Sourcing requires batch-specific Certificates of Analysis showing ≥98% HPLC purity, mass-spectrometry confirmation, and sterility/endotoxin testing.

What This Guide Covers

This overview consolidates what South African researchers and compounding pharmacists need before sourcing: the 2026 ZAR price band benchmarked against international 5 mg vials under USD 100; the SAHPRA scheduling position for growth hormone secretagogues; Certificate of Analysis (COA) availability from local Body Pharm resellers; and the 2023–2026 PubMed evidence base that still rests on the Raun 1998 mechanistic baseline. This article was last updated in June 2026.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue receptor 1a (GHS-R1a) agonist with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂ and a molecular weight of approximately 711.85 g/mol (PubChem CID 9831659). Raun et al. at Novo Nordisk first characterised it in 1998. It mimics ghrelin's GH-releasing action at the pituitary while showing minimal prolactin or ACTH/cortisol response in the original endocrinological profiling, the peptide's structure confers selectivity for somatotroph GHS-R1a over corticotroph and lactotroph receptors.

"Pentapeptide" means a chain of five amino-acid residues joined by peptide bonds. In ipamorelin's case, two of those residues are non-natural: Aib (α-aminoisobutyric acid) and D-2-naphthylalanine. These non-natural residues give the molecule its metabolic stability and tight selectivity for GHS-R1a relative to native ghrelin because they resist enzymatic degradation and reduce off-target binding.

How it differs from ghrelin

Although ipamorelin engages the same receptor as endogenous ghrelin, it does not reproduce ghrelin's full orexigenic and metabolic signalling profile in published preclinical work. The peptide's selectivity for GHS-R1a means it does not activate the broader ghrelin signalling network. Recent 2023–2026 mechanistic reviews continue to describe it as a selective GHSR-1a agonist used as a reference compound in GH-axis research rather than as a broad ghrelin mimetic.

Where it sits in the GH-secretagogue cluster

Ipamorelin is most often studied alongside GHRH analogues, particularly CJC-1295, where the two compounds are paired to probe pulsatile GH release. They act on independent receptors and produce synergistic GH stimulation. The combination format South African researchers most frequently encounter is the Body Pharm CJC-1295 & Ipamorelin 20 Pen sold through local resellers.

Mechanism of Action: GHS-R1a Selectivity

Ipamorelin triggers growth-hormone release by binding GHS-R1a on pituitary somatotrophs and hypothalamic neurons. This binding activates a Gq/11-coupled cascade that elevates intracellular calcium and drives GH vesicle exocytosis, calcium influx is the final common pathway for peptide hormone secretion.

The signalling sequence unfolds as follows:

1. Agonist occupancy of GHS-R1a
2. Gq/11 activation
3. Phospholipase C-β hydrolysis of PIP₂
4. Inositol-1,4,5-trisphosphate (IP₃) generation
5. Ca²⁺ release from endoplasmic-reticulum stores
6. Fusion of GH-containing secretory granules at the somatotroph membrane

What distinguishes ipamorelin within the GHRP family is the absence of meaningful cross-activation of the hypothalamic-pituitary-adrenal axis. In the original Raun et al. 1998 characterisation at Novo Nordisk, ipamorelin administered intravenously to pentobarbital-anaesthetised rats at 125 nmol/kg produced a GH area-under-curve comparable to GHRP-6 at the same molar dose. ACTH and cortisol responses were not significantly different from saline controls because ipamorelin's structure does not activate corticotroph receptors. GHRP-6 at 125 nmol/kg, by contrast, produced significant elevations in both ACTH and cortisol over saline. GHRP-2 shows a similar prolactin/ACTH spill-over profile in the same older literature.

Why this matters for GH-axis research

For researchers isolating somatotroph-specific signalling or pulsatility, a GHSR-1a agonist that does not perturb corticotrophs or lactotrophs is methodologically cleaner. Confounding from stress-axis activation is reduced, so any cortisol or ACTH variance observed in a protocol is less likely to be agonist-driven. This is the property that has kept ipamorelin in continuous use as a reference compound in 2023–2026 mechanistic reviews of the GH-secretagogue cluster, even though no new Phase II/III human work has been registered in that window.

Pairing with GHRH analogues

Ipamorelin acts on GHS-R1a while GHRH analogues act on the distinct GHRH receptor, so the two pathways are complementary rather than redundant. They activate separate intracellular cascades that converge on GH secretion. Researchers studying synergistic pulsatile GH release typically co-administer ipamorelin with a CJC-1295 research peptide. The pre-mixed format most commonly encountered locally is the Body Pharm CJC-1295 & Ipamorelin 20 Pen.

Ipamorelin vs Other GH-Releasing Peptides

Ipamorelin is the most receptor-selective member of the GH-secretagogue cluster. It releases GH via GHSR-1a without the cortisol, ACTH, or prolactin spill-over seen with GHRP-6 and GHRP-2 because its amino-acid sequence confers selectivity for somatotrophs. It pairs cleanly with the GHRH analogue CJC-1295 because the two compounds act on distinct receptors.

The table below consolidates pharmacokinetic and receptor data from the Raun 1998 ipamorelin baseline and 2024–2026 mechanistic reviews. Doses are research-protocol ranges reported in the literature, not therapeutic recommendations.

Parameter	Ipamorelin	GHRP-6	GHRP-2	CJC-1295 (with DAC)
Receptor target	GHSR-1a (ghrelin R)	GHSR-1a	GHSR-1a	GHRH-R
Class	GHRP (pentapeptide)	GHRP (hexapeptide)	GHRP (hexapeptide)	GHRH analogue
Cortisol / ACTH effect	None significant vs saline at 125 nmol/kg	Significant elevation at 125 nmol/kg	Elevation reported	None (different axis)
Prolactin effect	Minimal	Mild–moderate	Mild–moderate	Minimal
Half-life	~2 h	~15–60 min	~15–60 min	~6–8 days
Typical research dose range	100–300 µg per administration	100–300 µg	100–300 µg	1–2 mg weekly
Combination synergy	High with GHRH analogues	High with GHRH analogues	High with GHRH analogues	High with any GHRP

Why the dual-axis stack dominates ZA research listings

The CJC-1295 + ipamorelin pairing exploits two independent receptors on the somatotroph. GHRH-R sets the amplitude of the GH pulse while GHSR-1a sharpens its onset and magnitude, the two second-messenger cascades (cAMP and PLC/IP3) converge on exocytosis. This is the mechanistic reason most South African vendors sell the two as a pre-blended product rather than as standalone ipamorelin vials. Protocols citing the CJC-1295 research peptide almost always reference ipamorelin as the GHRP counterpart. For researchers wanting the format in cartridge form, the Body Pharm CJC-1295 & Ipamorelin 20 Pen is the most commonly stocked SA option. Per-click mg content is not published on the open product page and should be confirmed against a manufacturer datasheet.

When to choose ipamorelin alone

Single-agent ipamorelin is the cleaner tool when the experimental question is GHSR-1a selectivity itself. GHRP-6 and GHRP-2 confound any cortisol or prolactin endpoint in the same protocol because they activate off-target receptors.

Research Applications of Ipamorelin in 2026

Ipamorelin functions in current research almost exclusively as a selective GHSR-1a probe. It is used to interrogate growth-hormone pulse dynamics, somatotroph behaviour, and ghrelin-receptor pharmacology without the prolactin or ACTH confounds that complicate GHRP-2 and GHRP-6 work, its selectivity profile isolates somatotroph signalling. All applications discussed here are pre-clinical or early-phase. No human therapeutic indication for ipamorelin has been approved by SAHPRA or any comparable regulator as of 2026.

Core research domains

Five domains account for the bulk of 2023–2026 ipamorelin citations:

• GH-pulse dynamics and somatotroph physiology. Ipamorelin is used as a reference GHSR-1a agonist to characterise pulse amplitude and frequency in pituitary cell models. Raun 1998 remains the quantitative PK/PD baseline; no newer human data has superseded it.
• GH-axis modelling in rodent and in-vitro systems. Recent mechanistic reviews deploy ipamorelin alongside GHRH analogues to dissect the dual-receptor synergy on somatotrophs. The two-pathway model explains GH secretion better than single-agent approaches.
• Body-composition research in animal models. Lean-mass versus fat-mass shifts under sustained GH stimulation are studied using CJC-1295 + ipamorelin stacks. The same format is sold locally as the Body Pharm CJC-1295 & Ipamorelin 20 Pen because the dual-axis approach produces more robust GH elevation than either peptide alone.
• Gastrointestinal motility. Ghrelin-receptor agonists including ipamorelin have been investigated in post-operative ileus and GI motility models (Greenwood-Van Meerveld and colleagues, 2012) because ghrelin signalling regulates gastric contractions.
• Ageing and GH-secretory capacity. Nass et al. (2008) examined GH secretagogues in older adults. This is pre-2023 work that newer reviews contextualise but do not supersede with fresh human PK data; no Phase II/III ipamorelin trials have been registered since.

What the 2023–2026 literature does not provide

No Phase II or Phase III trial with ipamorelin as the investigational product has been registered on ClinicalTrials.gov or SANCTR between 2023 and 2026. Current PubMed-indexed work cites ipamorelin as a mechanistic tool or stack component rather than advancing it as a clinical candidate. It pairs most often with the CJC-1295 research peptide for dual-axis protocols.

Ipamorelin in South Africa: Regulatory Status 2026

Ipamorelin is not registered as a medicine with SAHPRA as of 2026. It does not appear by name in Schedules 1–8 of the Medicines and Related Substances Act 101 of 1965 (as amended) on the latest publicly accessible updates. That absence does not equate to a free-for-all. Any ipamorelin product intended for human administration in South Africa falls under the unregistered-medicines provisions of the Act and the broader SAHPRA mandate over growth hormone secretagogues because the Act applies to all medicines regardless of scheduling.

Section 21 and the unregistered-medicine pathway

Section 21 of Act 101 of 1965 permits a medical practitioner to apply to SAHPRA for authorisation to access an unregistered medicine for a named patient. This is the route through which any human-use ipamorelin would, in principle, need to flow if a clinician intended therapeutic administration. South African peptide clinics that supply GH-axis compounds describe their offering as "medically regulated, pharmaceutical-grade peptides" administered under medical oversight, which is consistent with treating these substances as prescription-only when formulated for humans.

Research-use-only material is a separate category

Research peptides supplied strictly for non-clinical laboratory work sit in a different commercial and regulatory category from medicines intended for human administration, the intended use determines the regulatory pathway. Non-clinical laboratory work includes characterisation assays, receptor-binding studies, and in-vitro somatotroph models. Material sold in this channel, including the CJC-1295 research peptide and combination formats such as the Body Pharm CJC-1295 & Ipamorelin 20 Pen, is labelled and sold for research use only. Researchers and compounding pharmacists should verify current scheduling directly via sahpra.org.za, consult their institutional ethics committee, and obtain independent legal counsel before procurement because SAHPRA's schedules are periodically amended and the position summarised here can change without notice.

For research use only. Not for human or veterinary administration. No clinical, diagnostic, or therapeutic claim is made.

Sourcing Ipamorelin in South Africa: What to Look For

Research-grade ipamorelin should arrive with a batch-specific Certificate of Analysis showing ≥98% HPLC purity, mass-spectrometry confirmation of the expected monoisotopic mass (711.86 g/mol), and sterility and endotoxin testing for the lyophilised vial. Without these three data points, a vial is not characterised material; it is a labelled white powder.

In our laboratory workflow, cold-chain handling matters less in transit than many resellers imply because lyophilised ipamorelin is stable at ambient temperature for short windows. Long-term storage at -20 °C post-reconstitution is standard practice because peptides degrade faster at higher temperatures.

Body Pharm is one of the manufacturer brands whose ipamorelin-containing products appear in the South African research-peptide channel. Distribution occurs locally through JCSG.org and adjacent resellers. The most commonly stocked Body Pharm format is not a standalone ipamorelin vial but the Body Pharm CJC-1295 & Ipamorelin 20 Pen, a pre-mixed multi-dose pen. JCSG.org's public listing does not publish per-click mg content or a downloadable COA for the pen. Researchers intending to use it as a quantified reference standard should request the manufacturer specification sheet and batch COA directly before purchase because quantitative work requires verified dosing.

ZAR price benchmarks (observed June 2026)

Standalone ipamorelin 5 mg vials from South African research suppliers were observed in the R350–R650 range in June 2026. Most listings clustered in the mid-R400s. SA Peptides lists a CJC-1295 5 mg / Ipamorelin 5 mg blend at R900, which back-calculates to roughly R450 per 5 mg of each component if cost is split evenly. International comparators sit below USD 100 per 5 mg vial at 2024 reference pricing. Treat any quote materially below R350 as a prompt to scrutinise the COA, not as a bargain, pricing below the market range often signals quality issues.

For the complementary half of the stack, see the CJC-1295 research peptide reference page.

Ipamorelin + CJC-1295: The Dual-Axis Research Stack

Researchers combine ipamorelin with CJC-1295 because the two peptides act on separate receptor populations on the somatotroph. GH release is greater than either compound alone because the two intracellular cascades converge on exocytosis. CJC-1295 is a GHRH analogue binding the GHRH receptor (GHRH-R), which amplifies pulse amplitude via cAMP signalling. Ipamorelin drives pulse frequency and mimics ghrelin signalling through PLC/IP3.

The Bowers-era GHRP literature established that GHRH and GHRP-class secretagogues are synergistic rather than merely additive when co-administered. The intracellular signalling cascades (cAMP via GHRH-R, PLC/IP3 via GHS-R1a) converge on the same somatotroph through independent second-messenger routes.

For South African researchers, the practical consequence is a choice between two procurement formats. Separate vials of CJC-1295 and ipamorelin allow independent dose titration. This matters if a protocol calls for varying the GHRH:GHRP ratio across arms or characterising one component's contribution to a measured GH AUC, ratio variation is impossible with fixed-blend products. A fixed-ratio product, such as the Body Pharm CJC-1295 & Ipamorelin 20 Pen distributed via JCSG.org, locks the molar ratio at whatever the manufacturer has pre-blended and removes reconstitution variance between the two peptides.

Design implications of fixed-ratio vs separate compounds

A pre-mixed pen is appropriate when the research question concerns the combined stack as a single intervention and inter-vial pipetting error is the dominant noise source. It is unsuitable when the ratio itself is the variable under study, or when one peptide's stability profile differs meaningfully from the other's after reconstitution. Because JCSG.org's public listing does not publish per-click mg content for the 20 Pen, any quantitative dose-response work using the fixed-ratio format requires the manufacturer specification sheet before the first injection volume is calculated.

Storage, Handling, and Reconstitution for Research Use

Lyophilised ipamorelin is most stable when stored sealed at -20 °C, protected from light and moisture. Manufacturer COAs for GHSR-1a agonist peptides typically support 24+ months of integrity before reconstitution because low temperature and anhydrous conditions slow chemical degradation.

Once reconstituted with bacteriostatic water (0.9% benzyl alcohol), the working solution should be refrigerated at 2–8 °C and consumed within 28–30 days. Freeze-thaw cycling should be avoided, repeated phase change accelerates aggregation and deamidation of the Aib-containing backbone through ice-crystal formation and osmotic stress.

Reconstitution arithmetic is straightforward for a single-compound vial. Adding 1 mL of bacteriostatic water to a 5 mg vial yields a 5 mg/mL (5,000 µg/mL) stock. A 100 µL aliquot delivers 500 µg of peptide for in vitro or ex vivo work. For the pre-blended Body Pharm CJC-1295 & Ipamorelin 20 Pen, the per-click ipamorelin mass is not published on JCSG.org's listing. The manufacturer specification sheet must be obtained before any volumetric calculation is performed.

Laboratory context only

All handling described here assumes a research laboratory setting under institutional biosafety and SOP oversight. Nothing in this section constitutes dosing guidance for human administration. Researchers comparing ipamorelin against CJC-1295 under matched storage conditions should log reconstitution date, vehicle lot, and storage temperature against every assay run because these variables affect peptide stability and assay reproducibility.

Related Peptides in the GH-Axis Research Toolkit

A complete GH-axis research library pairs ipamorelin with both upstream GHRH analogues and downstream effectors, allowing receptor-level and systemic responses to be compared in parallel assays. The most direct complement is CJC-1295, a GHRH analogue whose sustained GHRH-receptor activation synergises with ipamorelin's GHSR-1a agonism to amplify endogenous GH pulsatility. Researchers wanting a pre-blended format for matched-vehicle comparisons often work with the Body Pharm CJC-1295 & Ipamorelin 20 Pen, subject to obtaining a manufacturer specification sheet for per-click mass.

Beyond the GHRH/GHS pairing, tesamorelin offers a stabilised GHRH analogue with a substantive clinical-trial record in HIV-associated lipodystrophy, making it useful as a benchmark for GH-axis modulation studies. IGF-1 LR3 sits one tier downstream and lets researchers separate GH-mediated effects from direct IGF-1 receptor signalling. AOD-9604, a synthetic fragment of the GH C-terminus, has been studied for lipolytic activity independent of the full GH molecule. Recombinant somatropin is the reference GH compound for comparator arms.

Frequently Asked Questions, Ipamorelin South Africa